

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
for FY 2006

Complete if Known

Application Number	10/782,024
Filing Date	February 18, 2004
First Named Inventor	John G. Bauman
Examiner Name	Deborah D. Carr
Art Unit	1621
Attorney Docket No.	140140.401C1

☐ Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)**380.00****METHOD OF PAYMENT** (check all that apply)

- ☒ Check ☐ Credit Card ☐ Money Order ☐ Other (please identify): _____
- ☒ Deposit Account Deposit Account Number: 19-1090 Deposit Account Name: Seed IP Law Group PLLC
- For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)
- ☐ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, **except for the filing fee**
- ☐ Charge any additional fee(s) or underpayments ☒ Charge any underpayments or credit any overpayments of fee(s) under 37 CFR 1.16 and 1.17

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION** (All the fees below are due upon filing or may be subject to a surcharge.)**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Provisional	200	100	0	0	0	0	_____

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims
<u>17</u>	-20 or HP = <u>0</u>	X _____ = _____	_____	Fee (\$)

HP = highest number of total claims paid for, if greater than 20

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
<u>6</u>	-5 HP = <u>1</u>	X <u>200</u> = <u>200</u>	

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)) the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____	-100 = _____	/50 = _____ (round up to a whole number) x _____	_____	_____

4. OTHER FEE(S)

	Fees Paid (\$)
Non-English Specification, \$130 fee (no small entity discount)	_____
Other (e.g., late filing surcharge): <u>Supplemental Information Disclosure Statement</u>	<u>180</u>

SUBMITTED BY

Signature	<u>Carol J. Roth</u>	Registration No. (Attorney/Agent)	32,783	Telephone	206-622-4900
Name (Print/Type)	Carol J. Roth	Date	March 1, 2006		



EXPRESS MAIL NO. EV561559273US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John G. Bauman et al.
Application No. : 10/782,024
Filed : February 18, 2004
For : LIPOXIN A₄ ANALOGS
Examiner : Deborah D. Carr
Art Unit : 1621
Docket No. : 140140.401C1
Date : March 1, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Supplemental Information Disclosure Statement. Copies of all cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.


03/03/2006 AKELECH1 00000087 10782024

02 FC:1806

180.00 DP

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Carol J. Roth
Registration No. 32,783

CJR:ljt


Enclosures:

Supplemental Information Disclosure Statement
Cited References (4)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\752808

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 140140.401C1	APPLICATION NO. 10/782,024
	APPLICANTS John G. Bauman et al.	
	FILING DATE February 18, 2004	GROUP ART UNIT 1621



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AI					
	AJ					
	AK					
	AL					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	Bannenberg, G. et al., "Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration," <i>British Journal of Pharmacology</i> 143(1): 43-52, 2004.
AN	Fiorucci, S. et al., "A β -oxidation-resistant lipoxin A ₄ analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction," <i>Proc. Natl. Acad. Sci. USA</i> 101(44): 15736-15741, November 2, 2004.
AO	Guilford, W.J. et al., "Novel 3-Oxa Lipoxin A ₄ Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo," <i>Journal of Medicinal Chemistry</i> 47(8): 2157-2165, 2004.
AP	Guilford, W.J. et al., "Second-generation beta-oxidation resistant 3-oxa-lipoxin A ₄ analogs," <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 73: 245-250, 2005.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).